PCMA President releases statement on new GAO report

Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt released the following statement today on a new Government Accountability Office (GAO) report, "Medicare Part D Formularies: CMS Conducts Oversight of Mid-Year Changes; Most Mid-Year Changes Were Enhancements":

"While experts agree that pharmacy benefit managers (PBMs) help Part D come in under budget each year, GAO's new report provides fresh evidence that the Medicare drug benefit also expands access to new medications.

"GAO finds that 90 percent of the mid-year changes plans make to formularies are enhancements like covering a new drug. In the few cases when a drug is no longer covered, it's usually because a generic version of that drug has become available.

"This is in stark contrast to Medicaid's expensive, fee-for-service approach to pharmacy, which contributes to spiraling deficits in states all across America.

"According to a recent report, states and the federal government could save $33 billion – without cutting benefits for patients or payments to doctors and hospitals – by bringing Medicaid pharmacy benefits into the 21st century."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Dementia collaborative care delivers greater value than Alzheimer’s medication